MetaStat Aandeel

MetaStat Quick Ratio

De Snelle Ratio (Zuurtestratio) van MetaStat (MTST) per 17 aug 2026 bedraagt 0,16. In het voorgaande jaar bedroeg Snelle Ratio (Zuurtestratio) 0,41 — een verandering van -61,28% (lager).

Quick Ratio

0,16

YoY

-61,28%

Laatst bijgewerkt:

Snelle Ratio (Zuurtestratio) van MetaStat is 2026 0,16 . Snelle Ratio (Zuurtestratio) van MetaStat was 2025 0,41 . Het is daarmee -61,28% lager lager dan het jaar ervoor.
Access this data via the Eulerpool API

MetaStat Aandelenanalyse

Wat doet MetaStat? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel MetaStat

Snelle Ratio (Zuurtestratio) van MetaStat bedraagt 0,16 in 2026.

Snelle Ratio (Zuurtestratio) van MetaStat is veranderd van 0,41 naar 0,16, wat een verandering van -61,28% vertegenwoordigt. De waarde is lager dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Snelle Ratio (Zuurtestratio) MetaStat sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

De quick ratio meet de kortetermijnliquiditeit van een bedrijf zonder rekening te houden met voorraad.

Een 'goede' varieert per branche en bedrijfsfase. Op Eulerpool kunt u maatstaven direct vergelijken.

Access this data via the Eulerpool API

Hefboom — MetaStat

Alle kengetallen — MetaStat